Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory… EP News Bureau Oct 14, 2024 Intas Pharmaceuticals acquired exclusive commercialisation rights to DMB-3115 through a license agreement in 2021
